Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Medigene AG
MDG1Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company has research collaboration with WuXi Biologics to design and co-research TCR-guided T Cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. Medigene AG was founded in 1994 and is headquartered in Munich, Germany. Address: Lochhamer Strasse 11, Munich, Germany, 82152
Analytics
WallStreetin tavoitehinta
5.68 EURP/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut MDG1
Osinkoanalytiikka MDG1
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria MDG1
Osakkeen arvostus MDG1
Talousasiat MDG1
Tuloksia | 2019 | Dynamiikka |